

Supplement 1:

Figure S1 - Kaplan-Meier curves of Overall Survival and Cancer-specific Survival related to molecular subtypes, ypTNM/AJCC groups and ypN groups.





Figure S2 - Kaplan-Meier curves of Overall Survival and Cancer-specific Survival related to post-NACT nuclear grade, lymphovascular invasion and macroscopic pattern.



Supplement 2:

Table S1 - Univariate analysis of Overall Survival and Cancer-specific Survival - clinical data, treatment, and pre-treatment histopathologic data

	Overall		p-value	Specific Status		p-value
	Alive	Dead		Alive	Dead	
Age Years, Median IQI	48.5 (40-56)	46.5 (40.5-55.5)	0.675 ^M	49 (42-56)	46 (38-51)	0.112 ^M
Age group, years						
20-44	33 (31.1)	16 (40)	0.142 ^C	36 (31.9)	13 (44.8)	0.357 ^C
45-64	62 (60.8)	18 (45)		67 (59.3)	13 (44.8)	
64+	7 (6.9)	6 (15)		10 (8.8)	3 (10.3)	
Survival, months, Median (IQI)	29.5 (24.6-30.4)	17.8 (12-21.7)	<0.001 ^M	57.6 (47.7-60.8)	60.8 (57.6-0)	<0.001 ^M
Interval between last cycle						
NACT-surgery, days, Median (IQI)	175 (89-249)	138 (83-184.5)	0.097 ^M	170.5 (87-249)	147 (97-184.5)	0.344 ^M
Interval groups between NACT- surgery, n (%)						
≤ 90 days	26 (25.5)	12 (30.8)	0.222 ^C	31 (27.4)	7 (25)	0.771 ^Q
91 - 180 days	31 (30.4)	16 (41.0)		36 (31.9)	11 (39.3)	
>180 days	45 (44.1)	11 (28.2)		46 (40.7)	10 (35.7)	
Neoadjuvant chemotherapy regimen, n (%)						
Antraciline (AC)	5 (5)	1 (3.4)	0.690 ^C	5 (4.6)	1 (4.8)	0.887 ^Q
Antraciline+ Taxane	84 (83.2)	23 (79.3)		89 (81.7)	18 (85.7)	
Taxane	12 (11.9)	5 (17.2)		15 (13.7)	2 (9.5)	
Neoadjuvant trastuzumab, n (%)						
No	83 (84.7)	34 (100)	0.012 ^F	93 (86.1)	24 (100)	0.072 ^F
Yes	15 (15.3)	0 (0)		15 (13.9)	0 (0)	
Type of surgery						
Conservative	11 (10.5)	2 (5)	0.070 ^Q	11 (9.6)	2 (7.1)	0.211 ^Q
Mammary adenectomy	11 (10.5)	0 (0)		11 (9.6)	0 (0)	
Radical mastectomy	83 (79)	37 (94.6)		92 (80.7)	26 (92.9)	
Exclusive sentinel lymph node resection, n (%)						
Yes	33 (31.4)	6 (16.2)	0.089 ^F	34 (29.8)	5 (17.9)	0.244 ^F
No	72 (68.6)	31 (83.8)		80 (70.2)	23 (82.1)	
Clinical response, n (%)						
No response	1 (1.4)	5 (20.8)	<0.001 ^Q	3 (3.8)	3 (16.7)	0.014 ^Q
Partial response	36 (49.3)	17 (70.8)		40 (50.6)	13 (72.2)	
Complete response	36 (49.3)	2 (8.3)		36 (45.6)	2 (11.5)	
Adjuvant chemotherapy, n (%)						
No	59 (66.3)	16 (57.1)	0.379 ^Q	62 (64.6)	13 (61.9)	0.807 ^F
Yes	30 (33.7)	12 (42.9)		34 (35.4)	8 (38.1)	
Adjuvant trastuzumab, n (%)						

Supplement 2:

Table S1 - Univariate analysis of Overall Survival and Cancer-specific Survival - clinical data, treatment, and pre-treatment histopathologic data

	Overall		p-value	Specific Status		p-value
	Alive	Dead		Alive	Dead	
No	73 (79.3)	28 (90.3)	0.277 ^F	80 (80)	21 (91.3)	0.245 ^F
Yes	19 (20.7)	3 (9.7)		20 (20)	2 (8.7)	
Hormone therapy, n (%)						
No	31 (29.5)	18 (51.4)	0.024 ^F	35 (31)	13 (51.9)	0.047 ^F
Yes	74 (70.5)	17 (48.6)		78 (69)	14 (48.1)	
Adjuvant Radiotherapy, n (%)						
No	29 (32.6)	10 (38.5)	0.640 ^F	31 (33)	8 (38.1)	0.799 ^F
Yes	60 (67.4)	16 (61.5)		63 (67)	13 (61.9)	
Pre-treatment tumor size, cm, Median (IQI)						
Clinical stage (TNM/AJCC system), n (%)						
IA-IIA	5 (2.9-7)	6 (3-8)	0.064 ^M	5 (3-7)	6 (4-8)	0.097 ^M
IIB-IIIC	16 (15.2)	3 (8.1)		18 (15.8)	1 (3.6)	
Pre-treatment histologic type, n (%)						
Invasive carcinoma of no special type (ductal)	89 (84.8)	34 (91.9)	0.374 ^Q	96 (84.2)	27 (96.4)	0.416 ^Q
Invasive lobular carcinoma	91 (86.7)	34 (91.9)		100 (87.7)	25 (89.3)	
Others	8 (7.6)	3 (8.1)		8 (7)	3 (10.7)	
	6 (5.7)	0 (0)		6 (5.3)	0 (0)	

Notes: n – absolute frequency, % – percentage, IQI – Interquartile Interval, M – Mann-Whitney Test, C – Chi-Square Test, F – Fisher Exact Test.